INTRODUCTION
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) can elicit long-term remission in patients with chemotherapy-sensitive, relapsed, aggressive non-Hodgkin lymphoma (NHL) [1] . A key requirement for successful ASCT is the successful collection and cryopreservation of hematopoietic stem cells (HSCs) with a wellaccepted minimum target number of 2 Â 10 6 CD34þ cells/kg. Retrospective analyses have reported rates of mobilization failure in patients with NHL from approximately 20% to 30% with cytokines, either alone or in combination with chemotherapy [2] [3] [4] . Patients who are unable to collect this minimum number of HSCs often cannot proceed to ASCT [5] .
One assay used to screen for poor mobilizers is flow cytometric peripheral blood CD34þ enumeration. The number of circulating CD34þ cells measured before apheresis has been shown by some to correlate positively with stem cell yields in patients with hematologic malignancies. In published clinical studies, patients with preapheresis CD34þ cell counts above a threshold level, ranging from 5 to 34 CD34þ cells/mL, had significantly greater stem cell yields than those patients with lower preapheresis cell counts [6] [7] [8] . To date, however, the optimal preapheresis CD34þ cell count to predict mobilization success has not been determined, and there is no consensus on the preapheresis CD34þ threshold level that should be used to identify patients at risk for failed collection [6] [7] [8] .
Plerixafor is a first-in-class agent currently approved in the United States, in combination with granulocyte colonystimulating factor (G-CSF), to mobilize HSCs in patients with NHL or multiple myeloma [9] [10] [11] . Plerixafor is an inhibitor of the CXCR4 chemokine receptor that blocks receptor binding of the stromal cellederived factor-1a [12] . Disruption of the stromal cellederived factor-1aeCXCR4 interaction contributes to the release and trafficking of stem cells from the bone marrow into the peripheral blood and results in elevated levels of circulating HSCs both in humans and in animal models [13, 14] .
The efficacy and safety of plerixafor þ G-CSF in mobilizing stem cells in patients with NHL has been established in a phase III study (study 3101) [10] . Plerixafor þ G-CSF was shown to significantly increase the proportion of patients achieving optimal (!5 Â 10 6 ) CD34þ stem cell yields for ASCT in fewer apheresis days, compared with placebo þ G-CSF [10] . Additionally, plerixafor þ G-CSF in compassionate-use protocols was shown to effectively salvage patients with NHL who failed to mobilize peripheral blood stem cells after cytokines þ chemotherapy [4, 5, 15, 16] . Similarly, other published studies of plerixafor in combination with chemotherapy þ G-CSF in patients with NHL or multiple myeloma have shown the tolerability and preliminary efficacy of such a regimen in augmenting peripheral blood CD34þ cell count and subsequent HSC collection [17] [18] [19] .
Current guidelines acknowledge the potential impact of plerixafor on stem cell collection strategies, but debate over its optimal use remains, as outlined in a position paper on multiple myeloma [20] . The relatively large database from the plerixafor licensure study [10] provides information to assess any benefit for NHL patients with various levels of peripheral blood CD34þ cells/mL (<5, 5 to 9, 10 to 14, 15 to 19, or !20 cells/mL) after 4 days of G-CSF. The post hoc analyses presented here were conducted to assess the change in peripheral blood CD34þ cells/mL after addition of plerixafor or placebo on day 4 for apheresis start on day 5 and the subsequent effect on the total number of cells collected during apheresis and the ability of patients to proceed to transplantation. The potential limitation of data is that the study peripheral blood CD34þ cells/mL value was from a central laboratory, whereas the values used for decisions at the site were those of a local study site laboratory. Even so, these data may provide information about which patients benefit the most from plerixafor when G-CSF mobilization is used for NHL patients.
METHODS

Study Design
Post hoc analyses of patients enrolled in a phase III, randomized, double-blind, placebo-controlled study were performed to evaluate the safety and efficacy of plerixafor (.24 mg/kg s.c.) þ G-CSF (10 mg/kg/day s.c.)
versus placebo þ G-CSF in mobilizing CD34þ cells in patients with NHL [10] . Patients were stratified by threshold levels of peripheral blood CD34þ cells: <5, 5 to 9, 10 to 14, 15 to 19, or !20 CD34þ cells/mL, as measured on the morning of day 4, before the first plerixafor/placebo dose. The increase in peripheral blood CD34þ cells on day 5, the apheresis yields, the number of patients proceeding to transplantation, time to engraftment, and graft durability were compared between the plerixafor and placebo groups for patients with different thresholds of peripheral blood CD34þ cells/mL.
Patient Eligibility
Patient eligibility followed guidelines of the previously published 3101 study [10] . Key inclusion criteria were as follows: first or second complete or partial response to prior therapy, last cycle of chemotherapy completed !4 weeks before enrollment, Eastern Cooperative Oncology Group performance score of 0 or 1, white blood cell count >2.5 Â 10 9 cells/L, absolute neutrophil count >1.5 Â 10 9 cells/L, platelet count >100 Â 10 9 cells/L, serum creatinine 2.2 mg/dL, and liver function tests <2.5 Â upper limit of normal. Patients were not eligible if they had failed previous stem cell collection attempts, had prior stem cell transplantation, had received G-CSF within 14 days of the first dose of G-CSF on study, had >20% bone marrow involvement, or had received prior radioimmunotherapy. Patients who had their peripheral blood CD34þ cell counts measured on day 4, before apheresis, were included in these post hoc analyses [10] .
Mobilization and Transplantation
Patients received G-CSF (10 mg/kg) s. CD34þ cells/kg after 4 days of apheresis were eligible to enter an openlabel rescue protocol as described previously and are included in the analysis [10] .
Determination of Hematologic Parameters for Endpoint Analysis
Peripheral blood CD34þ cell count was measured within 30 minutes before G-CSF administration on the morning of day 4 (before plerixafor/ placebo treatment) and 10 to 11 hours after study drug treatment on the morning of day 5. Enumeration of CD34þ cells in peripheral blood and apheresis products was done by fluorescent activated cell sorter analysis at a local laboratory and a central laboratory (Esoterix, Inc., Austin, TX). The local laboratory values were used for all clinical decisions. Efficacy endpoints were calculated using the percentage of CD34þ cells determined by the central laboratory applied to the white blood cell count from the local laboratory. Neutrophil engraftment was defined as neutrophil count !.5 Â 10 9 /L for 3 days or !1.0 Â 10 9 /L for 1 day. Platelet engraftment was defined as platelet count !20 Â 10 9 /L without a transfusion for the preceding 7 days.
Statistical Analysis
For continuous outcomes, P values were calculated using Wilcoxon rank sum test. For dichotomous outcomes, P values were calculated using chi-square test. P < .05 was considered statistically significant, and all analyses were performed using SAS version 8.2 or above (SAS Institute., Cary, NC).
RESULTS
Patients
A total of 298 patients were enrolled in the 3101 study and randomized to receive either plerixafor þ G-CSF (n ¼ 150) or placebo þ G-CSF (n ¼ 148) [10] . Day 4 peripheral blood CD34þ cell counts were available for 132 patients (88.0%) in the plerixafor group and for 124 patients (83.8%) in the placebo group. Patients were stratified by threshold levels of peripheral blood CD34þ cells: <5, 5 to 9, 10 to 14, 15 to 19, or !20 CD34þ cells/mL. Baseline characteristics and patient demographics, by threshold group, are presented in Table 1 , including age, median time from diagnosis to progression, median time from most recent progression to randomization, and prior radiotherapy, and were not statistically different.
Efficacy
Peripheral blood CD34þ cells
Comparing plerixafor þ G-CSFetreated patients with placebo þ G-CSFetreated patients, the median absolute peripheral blood CD34þ cells/mL on day 4 were not significantly different between the 2 treatment arms for any of the 5 peripheral blood threshold groups (Table 2) . On day 5, however, the median absolute number of circulating peripheral blood CD34þ cells/mL in the plerixafor-treated group were significantly greater compared with the placebo-treated patients for all threshold groups (<5 cells/mL group: 14.3 versus 3.6 cells/mL; 5 to 9 cells/mL group: 36.6 versus 11.2 cells/mL; 10 to 14 cells/mL group: 57.8 versus 18.5 cells/mL; 15 to 19 cells/mL group: 80.3 versus 23 cells/mL; !20 cells/mL group: 113.4 versus 42 cells/mL; P < .001 for all plerixafor versus placebo comparisons in all threshold groups) ( Table 2 ).
CD34þ cell yields
During the first mobilization period, the peripheral blood stem cell collection yield was more than doubled for the plerixafor groups in all cases when the peripheral blood CD34þ cells/mL value was 15 ( Table 3 shows the apheresis yields for the placebo group and the plerixafor group separated into the 5 categories of peripheral blood CD34þcells/mL on day 4 (before either placebo or plerixafor dose). The collection of <1, 1 to <2, 2 to <5, and !5 Â 10 6 cells/kg is shown for the total apheresis period which could be 1 to 4 days (see Methods). These data show that (per the central reference laboratory) at least a peripheral blood count of 15 CD34þcells/mL was needed so that almost all patients collect 2 Â 
Transplantation and engraftment
In Table 2 , the number of cells infused for transplantation is given for each group of patients listed by initial peripheral blood CD34þ cells/mL value at day 4. However, the total is either that obtained during the first mobilization period only or a combination of cells from the first mobilization period plus the trial mandated rescue mobilization period. Those patients undergoing rescue are listed in the last horizontal row in the Table 2 . Therefore, in the predicted worst patients to mobilize (<5 CD34þ cells/mL on day 4), some of the plerixafor-treated patients (14/48; 29%) were not mobilized during the first mobilization period, whereas most of the placebo-treated patients (36/45; 80%) failed. When those failing to mobilize during the first mobilization period were then mobilized with G-CSF þ plerixafor and the combined yields were used for transplantation, the majority of both groups were transplanted. The 2 groups with peripheral blood CD34þ cells/mL values of <5 and 5 to 9 were mobilized at day 4, and there were fewer requiring rescue: in the plerixafor group (6/77; 8%) and in the placebo group (32/73; 44%). When the peripheral blood CD34þ cell/ul mL value was 10 to 14 in the placebo group, 25% (5/20) still needed rescue.
Engraftment
Postautologous HSCT, the median engraftment for every group for platelets was between 19 and 21 days and for neutrophils was 10 or 11 days (data not shown). All patients in both groups had durable grafts at 1 year, with the exception of 2 patients in the plerixafor arm (1 with <5 cells/mL and 1 with !20 cells/mL); as previously reported, 1 patient had myelodysplastic syndrome and the other remained clinically stable at the 18-month follow-up [10] . 
Median age (range), yr 
DISCUSSION
The goal of these post hoc analyses was to explore the efficacy of plerixafor in augmenting stem cell collection in patients with NHL across varying preapheresis circulating CD34þ cell thresholds. This task was facilitated by availing ourselves of two matched patient cohorts from the phase III randomized 3101 trial [10] . By stratifying patients in these analyses according to preapheresis levels of peripheral blood CD34þ cells, we hoped to understand the impact of plerixafor use on mobilization yields in patients with varying preapheresis CD34þ cell counts.
A positive effect of plerixafor on stem cell collection was observed across all peripheral blood CD34þ threshold groups, including the group with a preapheresis CD34þ cell count <20 cells/mL, composed of patients generally considered to be "slow" or "poor" mobilizers. Although there is no consensus on the preapheresis CD34þ threshold level that should be used to identify patients at risk for poor mobilization, previous studies have shown that patients with preapheresis CD34þ cell counts !20 cells/mL were significantly more readily mobilized with G-CSF AE chemotherapy and able to collect sufficient HSCs for ASCT than were patients with cell counts <20 cells/mL [8, 22] . If one accepts this level as "standard," then 80% of the patients included in this analysis of the 3101 study were considered at risk for poor mobilization, recognizing that >50% of patients treated with G-CSF þ placebo had CD34þ progenitors of <10/mL on day 4 ( Table 2 ). In our analysis, the median cumulative stem cell yield in patients with a preapheresis cell count <20 cells/mL treated with placebo þ G-CSF did not reach minimum collection targets, even after 4 days of apheresis, requiring that these patients underwent a second mobilization procedure, to pursue ASCT.
Treatment with plerixafor þ G-CSF significantly rescued these patients with low cell counts, providing strong support that the upfront use of plerixafor could benefit patients with preapheresis CD34þ cell counts <20 cells/mL who do not mobilize sufficiently with G-CSF alone (approximately 40% of cases), particularly in the setting where G-CSF is dosed by U.S. Food and Drug Administration label standards rather than at higher doses, as some single institutional studies have reported [23] . In particular, our analysis carries relevance for patients with preapheresis peripheral blood CD34þ cell counts <5 cells/mL who are consistently precluded from apheresis based on their low cell counts. Treatment with plerixafor þ G-CSF allowed more than 70% of these patients to reach minimum stem cell collection targets.
The obvious question is what is the "low" peripheral blood CD34þ cells/mL value that provides the most benefit of all for the use of plerixafor? Every patient in both groups with a CD34þ cell/mL value of ! 20 was able to be mobilized for transplantation. The only potential benefit of plerixafor was to use it in fewer apheresis procedures or to mobilize more cells [10] . Other potential reasons to use plerixafor at this level of CD34þ cells/mL include presentation of risk factors for poor mobilization (age, prior chemotherapy, prior fludarabine or lenalidomide exposure, etc.) and the need for predictable cell collection. Patients with 15 to 19 CD34þ cells/mL likewise all mobilized at !2 Â 10 6 CD34þ cells/kg.
However, when there were <15 CD34þ cells/mL, 25% or more of patients who did not receive plerixafor failed to mobilize and collect enough cells for transplantation. At <5 CD34þ cells /mL, G-CSF alone was clearly unacceptable without a subsequent rescue mobilization in these NHL patients. At the same level of CD34þ cells/mL, plerixafor þ G-CSF was 
Median absolute peripheral blood CD34þ cells/mL 20 (100) 12 (100) 8 (88.8)
15 (100) 22 (100) 28 ( successful in 34 of 48 patients (71%). Thus, in the predicted worst patients, G-CSF þ plerixafor can be a viable means to mobilize peripheral blood stem cell in NHL patients, especially when chemomobilization may not be appropriate. Although it is current standard practice for stem cell transplant centers to determine CD34þ cell counts before apheresis, one must recognize the potential variability in these assays. There can be center-to-center variability in the preapheresis cell count threshold used to predict collection failure. Precollection CD34þ enumeration is more predictive after G-CSF þ chemotherapy mobilization compared with G-CSF alone, because CD34þ cells can be counted more accurately with a lower coefficient of variability in the background of low circulating leukocytes after G-CSF þ chemotherapy than in the background of high circulating leukocytes after G-CSF alone [24] . As a result, some centers will dilute the circulating white blood count in this setting to normalize the collection. Furthermore, the variability that arises from differing cell quantification methods effectively precludes cross-study comparisons that may allow clinical validation of a specific cell count threshold as a predictor of mobilization success [25] .
We recognize that individual institutions set their own algorithms for utilization of preapheresis CD34þ cell count to guide the apheresis decision; however, given the potential variability, such algorithms need to be prospectively and institutionally validated. Continued clarification of this issue of CD34þ cell count assessment is a necessary hurdle toward the goal of developing standard treatment guidelines outlining the optimal use of plerixafor in patients with NHL and other hematologic malignancies. To this end, our findings provide significant insight into the specific patient population that may derive the greatest benefit from plerixafor treatment, an important step toward defining the optimal use of this drug.
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